Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes

Circulation Research

Volumn 106, Issue 5, 2010, Pages 932-940

  Weskamp, Gisela ^a   Mendelson, Karen ^a   Swendeman, Steve ^a   Le Gall, Sylvain ^a   Ma, Yan ^b   Lyman, Stephen ^b   Hinoki, Akinari ^c   Eguchi, Satoru ^c   Guaiquil, Victor ^a   Horiuchi, Keisuke ^c,d   Blobel, Carl P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Adams; Metalloproteinase disintegrins; Pathological neovascularization; Proliferative retinopathy; Tnf convertase

Indexed keywords

ANGIOPOIETIN RECEPTOR; CRE RECOMBINASE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULOTROPIN RECEPTOR 2; ACTIN; ADAM PROTEIN; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; INTEGRASE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; TEK PROTEIN, MOUSE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOLOGY; ENDOTHELIUM CELL; GENE INACTIVATION; GENE SILENCING; HOMEOSTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SMOOTH MUSCLE FIBER; TUMOR CELL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; ENZYMOLOGY; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROMOTER REGION; SWINE; TIME; TUMOR VOLUME; VASCULARIZATION;

ACTINS; ADAM PROTEINS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; INTEGRASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROMOTER REGIONS, GENETIC; RECEPTOR PROTEIN-TYROSINE KINASES; RETINAL NEOVASCULARIZATION; SWINE; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77950889362     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.207415     Document Type: Article

References (40)

1. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3:89-96.
2. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
3. Khong TL, Larsen H, Raatz Y, Paleolog E. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis. 2007;10:243-258.
4. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis. 2007;10:141-148.
5. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
6. Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S, Blobel CP. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ Res. 2008;103:916-918.
7. Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y, Blobel CP. Cutting edge: TNF-{alpha}-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J Immunol. 2007;179:2686-2689.
8. Black R, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloprotease disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385:729-733.
9. Moss ML, Jin S-LC, Milla ME, Burkhart W, Cartner HL, Chen W-J, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Lessnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su J-L, Warner J, Willard D, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature. 1997;385:733-736.
10. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756.
11. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russel WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281-1284.
12. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, Lee DC. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 2003;22:2704-2716.
13. Blobel CP. ADAMs: key players in EGFR-signaling, development and disease. Nat Rev Mol Cell Bio. 2005;6:32-43.
14. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment Nat Rev Cancer. 2008;12:929-941.
15. Sahin U, Weskamp G, Zhou HM, Higashiyama S, Peschon JJ, Hartmann D, Saftig P, Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR-ligands. J Cell Biol. 2004;164:769-779.
16. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230-242.
17. Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, Manova K, Blobel CP. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol. 2003;23:5614-5624.
18. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro P, Blobel CP. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol. 2009;29:2694-2703.
19. Lim YC, Luscinskas FW. Isolation and culture of murine heart and lung endothelial cells for in vitro model systems. Methods Mol Biol. 2006;341:141-154.
20. Le Gall S, Bobe P, Reiss K, Horiuchi K, Niu X-D, Lundell D, Gibb D, Conrad D, Saftig P, Blobel C. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as TGFα, L-Selectin and TNFα. Mol Biol Cell. 2009;20:1785-1794.
21. Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K, Elenius K. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J. 2003;17:1609-1621.
22. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 1994;91:2890-2894.
23. Mehta VB, Besner GE. HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors. 2007;25:253-263.
24. Clarke PA, Dickson JH, Harris JC, Grabowska A, Watson SA. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res. 2006;66:3504-3512.
25. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, Fang L, Lee SW. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004;64:5283-5290.
26. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T. Angiotensin AT (1) and AT (2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res. 2001;88:22-29.
27. Hollborn M, Iandiev I, Seifert M, Schnurrbusch UE, Wolf S, Wiedemann P, Bringmann A, Kohen L. Expression of HB-EGF by retinal pigment epithelial cells in vitreoretinal proliferative disease. Curr Eye Res. 2006;31:863-874.
28. Gridley T. Notch signaling in vascular development and physiology. Development. 2007;134:2709-2718.
29. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5:207-216.
30. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 2000;14:1343-1352.
31. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, Saftig P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet. 2002;11:2615-2624.
32. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7-19.
33. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N, Yang G, Li Y, Yao W, Vaddi K, Gazdar AF, Friedman SM, Jablons DM, Newton RC, Fridman JS, Minna JD, Scherle PA. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006;10:39-50.
34. Mohammed FF, Smookler DS, Taylor SE, Fingleton B, Kassiri Z, Sanchez OH, English JL, Matrisian LM, Au B, Yeh WC, Khokha R. Abnormal TNF activity in Timp3-/-mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004;36:969-977.
35. Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol. 2005;166:1733-1740.
36. Kwak HI, Mendoza EA, Bayless KJ. ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices. Matrix Biol. 2009;28:470-479.
37. Auricchio A, Behling KC, Maguire AM, O'Connor EM, Bennett J, Wilson JM, Tolentino MJ. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6:490-494.
38. Janssen A, Hoellenriegel J, Fogarasi M, Schrewe H, Seeliger M, Tamm E, Ohlmann A, May CA, Weber BH, Stohr H. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest Ophthalmol Vis Sci. 2008;49:2812-2822.
39. Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS, Peschon JJ, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Lee DC. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem. 2002;277:12838-12845.
40. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, Toyama Y, Hartmann D, Saftig P, Blobel C. Substrate Selectivity of EGF-Receptor Ligand Sheddases and Their Regulation by Phorbol Esters and Calcium Influx. Mol Biol Cell. 2007;18:176-188.